ACell, Inc. Sustainability Profile
ACell, Inc., a leading innovator in regenerative medicine, is headquartered in the United States, with significant operations across various regions. Founded in 1999, the company has established itself in the biotechnology industry, focusing on advanced wound care and surgical reconstruction solutions. ACell's core products, including its unique MatriStem® technology, utilise porcine-derived extracellular matrix to promote tissue regeneration and healing. This innovative approach sets ACell apart, offering effective solutions for complex wounds and surgical applications. With a strong market position, ACell has achieved notable milestones, including FDA approvals and partnerships that enhance its product offerings. The company continues to be at the forefront of regenerative medicine, committed to improving patient outcomes through its cutting-edge technologies.
DitchCarbon Score
How does ACell, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
ACell, Inc.'s score of 39 is higher than 65% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
ACell, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Integra LifeSciences Holdings Corporation, which may influence its climate commitments and emissions reporting. As of now, ACell, Inc. has not established any documented reduction targets or commitments to the Science Based Targets initiative (SBTi). The absence of specific emissions data and reduction initiatives suggests that ACell may be in the early stages of developing its climate strategy. The emissions data and performance metrics for ACell are inherited from its parent company, Integra LifeSciences Holdings Corporation, which operates at a cascade level of 1. This relationship may provide a framework for future climate commitments and emissions reductions as ACell aligns with the broader sustainability goals of its parent organisation. In summary, while ACell, Inc. currently lacks specific emissions data and reduction targets, its affiliation with Integra LifeSciences Holdings Corporation may play a crucial role in shaping its future climate initiatives.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 13,902,000 | 00,000,000 | 0,000,000 | 00,000,000 |
| Scope 2 | 18,609,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | 000,000,000 | 000,000,000 | 00,000,000 |
How Carbon Intensive is ACell, Inc.'s Industry?
How Carbon Intensive is ACell, Inc.'s Location?
ACell, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
ACell, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
